Platelet Indices Altered in Severe Malaria
|
By LabMedica International staff writers Posted on 08 Jan 2014 |

Image: Photomicrograph shows a growing Plasmodium vivax trophozoite in a blood smear (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).
Changes in platelet counts during acute malaria are common and such changes are a major cause of concern to clinicians because such cases are more likely to evolve into serious and complicated disease.
The reduction in the number of platelets, platelet function is also compromised in these patients suffering from acute malaria infection and this is generally evidenced by changes in the volume and other features of platelet cells.
Scientists at the University Hospital of Federal University of Mato Grosso (Cuiabá, Brazil) performed a cross-sectional descriptive study based on the clinical and laboratory data of 186 patients with acute malaria caused by Plasmodium vivax who attended the Malaria Clinic between 2008 and 2013. All the patients underwent hemogram and blood biochemical analyses at their first appointment and malaria was diagnosed on the basis of the microscopic examination of Giemsa-stained thick smears.
All blood cell counts were determined using the Pentra 80 automated equipment (Horiba Medical; Montpellier, France), which provides results for mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT). The normal ranges for MPV, PDW, and PCT provided for this equipment are 7.0/µm3–10.5/µm3, 11%–18%, and 0.15%–0.50% respectively. Patients with a longer duration of symptoms or those identified as primo infected were considered potential candidates for evolution into the severe form of malaria.
The MPV, PDW, and PCT values exhibited significant variability. A significant inverse relationship was observed between parasitaemia and PCT. Patients with warning signs for evolution into severe disease, with primo infection, or presenting with symptoms for over three days had the highest MPV and PDW. The mean platelet count was 114,823 ± 76,761 cells/mm3; 16.7% of the patients exhibited counts fewer than 50,000/mm3 and 60.7% had platelet counts between 50,000/mm3 and 150,000/mm3. The mean MPV was 9.3 µm, the mean PDW was 17.5% and mean PCT was 0.104%. Potentially more serious cases, that is, primo-infected patients, exhibited significantly higher MPV and PDW.
The authors concluded that that platelet indices were altered during acute and symptomatic infection by P. vivax. The elevation of MPV and PDW, and reduction of PCT are related to known potential risk factors for evolution into severe malaria, such as primo infection, longer symptom duration, and the presence of the classical warning signs of severe and complicated P. falciparum malaria. Therefore, these parameters and indices could be useful as predictors of severity in the clinical approach of patients with malaria caused by P. vivax. The study was published on December 27, 2013, in the Malaria Journal.
Related Links:
University Hospital of Federal University of Mato Grosso
Horiba Medical
The reduction in the number of platelets, platelet function is also compromised in these patients suffering from acute malaria infection and this is generally evidenced by changes in the volume and other features of platelet cells.
Scientists at the University Hospital of Federal University of Mato Grosso (Cuiabá, Brazil) performed a cross-sectional descriptive study based on the clinical and laboratory data of 186 patients with acute malaria caused by Plasmodium vivax who attended the Malaria Clinic between 2008 and 2013. All the patients underwent hemogram and blood biochemical analyses at their first appointment and malaria was diagnosed on the basis of the microscopic examination of Giemsa-stained thick smears.
All blood cell counts were determined using the Pentra 80 automated equipment (Horiba Medical; Montpellier, France), which provides results for mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT). The normal ranges for MPV, PDW, and PCT provided for this equipment are 7.0/µm3–10.5/µm3, 11%–18%, and 0.15%–0.50% respectively. Patients with a longer duration of symptoms or those identified as primo infected were considered potential candidates for evolution into the severe form of malaria.
The MPV, PDW, and PCT values exhibited significant variability. A significant inverse relationship was observed between parasitaemia and PCT. Patients with warning signs for evolution into severe disease, with primo infection, or presenting with symptoms for over three days had the highest MPV and PDW. The mean platelet count was 114,823 ± 76,761 cells/mm3; 16.7% of the patients exhibited counts fewer than 50,000/mm3 and 60.7% had platelet counts between 50,000/mm3 and 150,000/mm3. The mean MPV was 9.3 µm, the mean PDW was 17.5% and mean PCT was 0.104%. Potentially more serious cases, that is, primo-infected patients, exhibited significantly higher MPV and PDW.
The authors concluded that that platelet indices were altered during acute and symptomatic infection by P. vivax. The elevation of MPV and PDW, and reduction of PCT are related to known potential risk factors for evolution into severe malaria, such as primo infection, longer symptom duration, and the presence of the classical warning signs of severe and complicated P. falciparum malaria. Therefore, these parameters and indices could be useful as predictors of severity in the clinical approach of patients with malaria caused by P. vivax. The study was published on December 27, 2013, in the Malaria Journal.
Related Links:
University Hospital of Federal University of Mato Grosso
Horiba Medical
Latest Hematology News
- New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
- Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
- Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Channels
Clinical Chemistry
view channel
Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more
New Chairside Oral Swab Test Could Guide Biopsy Decisions in Oral Cancer
Oral squamous cell carcinoma can be difficult to triage at the point of care, resulting in frequent biopsies of lesions that ultimately prove benign. Limited access to pathology services in many communities... Read moreMolecular Diagnostics
view channel
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read morePathology
view channel
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more





 Assay.jpg)

